20120197.TNBC
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- WNT_BETA_CATENIN_SIGNALING+0.310
- HEDGEHOG_SIGNALING+0.290
- ANGIOGENESIS+0.280
- MYOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- E2F_TARGETS+0.200
- NOTCH_SIGNALING+0.170
- UV_RESPONSE_DN+0.170
- G2M_CHECKPOINT+0.120
- KRAS_SIGNALING_DN+0.110
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.510
- PI3K_AKT_MTOR_SIGNALING-0.470
- MTORC1_SIGNALING-0.450
- ESTROGEN_RESPONSE_EARLY-0.420
- INTERFERON_GAMMA_RESPONSE-0.420
- PROTEIN_SECRETION-0.410
- OXIDATIVE_PHOSPHORYLATION-0.390
- ESTROGEN_RESPONSE_LATE-0.370
- CHOLESTEROL_HOMEOSTASIS-0.350
- ANDROGEN_RESPONSE-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-58-8388-01A-11R-2326-07 | — | cohortSQ1 | 0.843 |
| 2 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.842 |
| 3 | SRR2777217 | — | — | 0.826 |
| 4 | TCGA-BA-4078-01A-01R-1436-07 | — | — | 0.820 |
| 5 | SRR8613798 | — | D | 0.816 |
| 6 | TCGA-63-A5MW-01A-11R-A26W-07 | — | cohortMD1 | 0.809 |
| 7 | SRR8518444 | — | D | 0.808 |
| 8 | TCGA-90-A4ED-01A-31R-A24Z-07 | — | cohortMD1 | 0.801 |
| 9 | SRR6013547 | — | cohortMD1 | 0.795 |
| 10 | SRR1313145 | — | D | 0.790 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| MYOGENESIS | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.200 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.170 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.170 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.100 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.060 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.020 | Idelalisib | — uncovered |